Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kronos Bio Inc (NQ: KRON )

0.9351 -0.0249 (-2.59%)
Streaming Delayed Price Updated: 1:42 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,659,168
Open 0.9548
Bid (Size) 0.9351 (6)
Ask (Size) 0.9400 (1)
Prev. Close 0.9600
Today's Range 0.9200 - 0.9976
52wk Range 0.7310 - 2.290
Shares Outstanding 56,769,091
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023
KRON stock results show that Kronos Bio beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Recap: Kronos Bio Q4 Earnings
Via Benzinga

Performance

YTD
-22.07%
-22.07%
1 Month
-23.98%
-23.98%
3 Month
-12.61%
-12.61%
6 Month
+3.90%
+3.90%
1 Year
-28.07%
-28.07%

More News

Read More
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
From Kronos Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study
Via Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
From Kronos Bio, Inc.
Via GlobeNewswire
Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
From Kronos Bio, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.